Evidence from the Real World Provides New Insights into the Evolving Landscape of Cancer Immunotherapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 129
Special Issue Editors
Interests: thoracic malignancies; immunotherapy; real-world outcome research; biomarkers
Interests: gastrointestinal malignancies; immunotherapy; real-world outcome research; biomarkers
Special Issue Information
Dear Colleagues,
Immunotherapy has profoundly changed the therapeutic landscape for many types of solid cancer. While we are witnessing the introduction of novel immune checkpoint inhibitors and combination regimens into clinical practice, as well as expanded therapeutic indications, several controversies still remain to be addressed. Real-world studies have proven valuable as they bridge the gap between clinical trials and routine practice, shedding light on issues that would otherwise be difficult to examine through prospective research. These include, but are not limited to, challenges related to concurrent loco-regional treatments or arising from the concomitant use of medications required for relevant comorbidities or to support cytotoxic and targeted therapies. This Special Issue of Cancers aims to showcase new research articles and timely reviews on the management of clinical practice issues during immune checkpoint blockade in solid malignancies.
Dr. Fabrizio Nelli
Dr. Carlo Signorelli
Dr. Enzo Ruggeri
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune-checkpoint inhibitors
- solid tumors
- cytotoxic chemotherapy
- targeted therapies
- radiotherapy
- concomitants medications
- supportive therapies
- real-world investigation
